首页> Clinical genitourinary cancer> Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.

Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Alejo,Rodriguez-Vida

第一单位： Medical Oncology Department, Hospital del Mar, IMIM Research Institute, Barcelona, Spain. Electronic address: arodriguezvida@hospitaldelmar.cat.

作者： Alejo,Rodriguez-Vida ^[1] ; Andrés,Rodríguez-Alonso ^[2] ; Eduardo,Useros-Rodríguez ^[3] ; Fernando,Lopez-Campos ^[4] ; Oscar,Amor-Carro ^[5] ; Alberto,Arribas-Ruiz ^[6] ; Javier,Martinez-Torres ^[7] ; Javier,Roca-Pardiñas ^[8] ; Alba,Quesada-García ^[9] ; Jacobo R,Muñoz-Del-Toro ^[5] ; Álvaro,Juárez-Soto ^[9]

作者单位： Medical Oncology Department, Hospital del Mar, IMIM Research Institute, Barcelona, Spain. Electronic address: arodriguezvida@hospitaldelmar.cat. ^[1] Urology Department, Complexo Universitario de Ferrol, Coruña, Spain. ^[2] Urology Department, Infanta Elena University Hospital, Madrid, Spain. ^[3] Radiation Oncology Department. Ramón y Cajal University Hospital, Madrid, Spain. ^[4] Medical Affairs Department, Janssen, Madrid, Spain. ^[5] Market Access, Janssen, Madrid, Spain. ^[6] Applied Mathematics Department, University of Vigo, Vigo, Pontevedra, Spain. ^[7] Statistics and Operational Research Department, University of Vigo, Vigo, Pontevedra, Spain. ^[8] Urology Department, Jerez University Hospital, Cádiz, Spain. ^[9]

关键词 Apalutamide Darolutamide Enzalutamide Next-generation anti-androgens Survival analysis

医学主题词雄激素拮抗药(Androgen Antagonists);雄激素受体拮抗剂(Androgen Receptor Antagonists);人类(Humans);免疫疗法(Immunotherapy);男(雄)性(Male);比例危险度模型(Proportional Hazards Models)

DOI 10.1016/j.clgc.2021.11.008

PMID 34920959

发布时间 2022-06-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交